Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03082352Phase 1Unknown

Clinical Bioequivalence Study on Two Metoprolol Tablet 100mg Formulations

Role: lead

NCT03599466Phase 1Unknown

Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations

Role: lead

NCT03210025Phase 1Completed

Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations

Role: lead

NCT02707913Phase 1Completed

Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations

Role: lead

NCT02643329Phase 1Completed

Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

Role: lead

All 5 trials loaded